Clinical Trials Logo

NLRC4-MAS clinical trials

View clinical trials related to NLRC4-MAS.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03512314 Active, not recruiting - NLRC4-MAS Clinical Trials

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension

Start date: January 24, 2018
Phase: Phase 3
Study type: Interventional

This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd. ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953). This OLE study will evaluate the long-term safety and tolerability of Tadekinig alfa in patients suffering from pediatric monogenic autoinflammatory diseases harboring deleterious mutations of NLRC4 and XIAP.